- Home
- NAGE vs ELVN Comparison
NAGE vs ELVN Comparison
Compare NAGE & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAGE
- ELVN
- Stock Information
- Founded
- NAGE 1999
- ELVN 2016
- Country
- NAGE United States
- ELVN United States
- Employees
- NAGE N/A
- ELVN N/A
- Industry
- NAGE Medicinal Chemicals and Botanical Products
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- NAGE Health Care
- ELVN Health Care
- Exchange
- NAGE Nasdaq
- ELVN Nasdaq
- Market Cap
- NAGE 861.0M
- ELVN 927.8M
- IPO Year
- NAGE N/A
- ELVN 2020
- Fundamental
- Price
- NAGE $11.73
- ELVN $19.14
- Analyst Decision
- NAGE Strong Buy
- ELVN Strong Buy
- Analyst Count
- NAGE 2
- ELVN 4
- Target Price
- NAGE $12.00
- ELVN $37.25
- AVG Volume (30 Days)
- NAGE 1.2M
- ELVN 361.5K
- Earning Date
- NAGE 05-07-2025
- ELVN 05-14-2025
- Dividend Yield
- NAGE N/A
- ELVN N/A
- EPS Growth
- NAGE N/A
- ELVN N/A
- EPS
- NAGE 0.18
- ELVN N/A
- Revenue
- NAGE $107,925,000.00
- ELVN N/A
- Revenue This Year
- NAGE $25.46
- ELVN N/A
- Revenue Next Year
- NAGE $21.72
- ELVN N/A
- P/E Ratio
- NAGE $65.43
- ELVN N/A
- Revenue Growth
- NAGE 29.77
- ELVN N/A
- 52 Week Low
- NAGE $2.31
- ELVN $13.30
- 52 Week High
- NAGE $11.79
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- NAGE N/A
- ELVN 57.11
- Support Level
- NAGE N/A
- ELVN $15.81
- Resistance Level
- NAGE N/A
- ELVN $17.54
- Average True Range (ATR)
- NAGE 0.00
- ELVN 1.34
- MACD
- NAGE 0.00
- ELVN 0.11
- Stochastic Oscillator
- NAGE 0.00
- ELVN 64.66
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.